Scinai Immunotherapeutics Ltd
SCNI
Company Profile
Business description
Scinai Immunotherapeutics Ltd is a biopharmaceutical company with two complementary business units: (i) Scinai R&D, focused on the development of therapeutics in inflammation and immunology, and (ii) the contract development and manufacturing organization (CDMO) business. The CDMO business provides integrated development and manufacturing services to small and emerging biotech companies, supporting clients from early-stage development through clinical-stage production.
Contact
Hadassah Ein Kerem Campus
2nd Floor, Jerusalem BioPark
Jerusalem
ISRT: +972 89302529
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
45
Stocks News & Analysis
stocks
Cheap Dividend Aristocrat has Fair Value raised after earnings
Dividend forecasts raised after balance sheet regains strength.
stocks
Why great earnings haven't been good enough for AI hardware stocks
Stocks that had been posting triple-digit returns are sliding on earnings results.
stocks
Fair Value increased for Big 4 bank after earnings
Shares still overvalued, with analysts thinking the fundamentals no longer matter to the share price.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,303.50 | 29.30 | -0.31% |
| CAC 40 | 8,650.56 | 24.38 | -0.28% |
| DAX 40 | 26,299.74 | 31.33 | -0.12% |
| Dow JONES (US) | 53,839.99 | 69.72 | 0.13% |
| FTSE 100 | 10,772.67 | 60.48 | -0.56% |
| HKSE | 25,160.25 | 236.26 | -0.93% |
| NASDAQ | 26,803.03 | 214.54 | 0.81% |
| Nikkei 225 | 68,596.52 | 287.93 | 0.42% |
| NZX 50 Index | 13,821.20 | 4.10 | -0.03% |
| S&P 500 | 7,798.99 | 50.49 | 0.65% |
| S&P/ASX 200 | 9,106.80 | 28.30 | -0.31% |
| SSE Composite Index | 3,918.65 | 8.31 | -0.21% |